Evidence map›Paper›PMID 41073977›Full record

SynthesisBMC infectious diseases2025

Efficacy of novel SARS-CoV2 vaccines in preventing SARS- CoV- 2 infection: a systematic review and meta-analysis.

Zigale Hibstu Teffera, Wubetu Yihunie Belay, Bantayehu Addis Tegegne, Habtamu Belew, Adane Adugna, Yasabe Laykun, Samrawit Tefera, Yalew Muche, Abateneh Melkamu, Gashaw Azanaw Amare and 9 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zigale Hibstu TefferaDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia. zigale.35@gmail.com.
Wubetu Yihunie BelayDepartment of Pharmacy, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Bantayehu Addis TegegneDepartment of Pharmacy, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Habtamu BelewDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Adane AdugnaDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Yasabe LaykunDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Samrawit TeferaDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Yalew MucheDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Abateneh MelkamuDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Gashaw Azanaw AmareDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Desalegn AbebawDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Yibeltal AkelewDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Mohammed JemalDepartment of Biomedical Sciences, School of Medicine, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Mamaru GetinetDepartment of Biomedical Sciences, School of Medicine, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Enyew Fenta MengistDepartment of Biomedical Sciences, School of Medicine, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Temesgen BaylieDepartment of Biomedical Sciences, School of Medicine, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Aysheshim Belaineh HaimanotDepartment of Public Health, College of Health Sciences, Debre Markos University, P. O. Box, 269, Debre Markos, Ethiopia.
Tiruzer HibistuDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.
Kassaye EnchalewDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, P. O, Box, 269, Debre Markos, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEfficacious SARS-CoV-2 vaccines are urgently required to prevent the spread of the emerging and re-emerging SARS-CoV-2.

objectiveAim to assess the efficacy of novel SRAS-CoV-2 vaccines in preventing SARS-CoV-2 infection.

methodsAll randomized placebo-controlled clinical trials eligible for this review were included. Scopus, PubMed, the Cochrane Library, and Google Scholar were searched. The risk of bias in the included studies was assessed using the modified Cochrane risk of bias tool 2 for RCTs. Result synthesis was performed using STATA software version 17.4. Forest plots, heterogeneity tests, meta-regression, sensitivity analysis, and publication bias were used to present the results.

resultEighteen studies comprising 186,657 participants who took the full dose of SARS-CoV-2 in an RCT were included. Of the participants, 110,768 (59.3%) were males and 111,619 (59.8%) were treatment groups. A total of 5665 (3.0%) participants were infected by SARS-CoV-2. Among the treatment groups, 3140 (2.8%) and 2525 (3.4%) from the placebo group were infected by SARS-CoV-2. The most efficient SARS-CoV-2 vaccine was BNT162B2, with 100% efficacy, whereas mRNA-1273 was the least efficient vaccine, with 36.8% efficacy. The overall efficacy of novel SRAS-CoV-2 vaccines was 70.5% (95% confidence interval (CI), 53.5 to 79.7). The relative risk of being infected was 84% lower in the treatment group compared to the placebo group. The novel SRAS-CoV-2 vaccines are efficient enough to protect 771 people out of 1000 from being infected by SARS-CoV-2. DISCUSSION: Novel SARS-CoV-2 vaccines are efficacious inn preventing SARS-CoV-2 infection. However, their efficacy varies.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2Vaccine EfficacyHumansRandomized Controlled Trials as TopicCOVID-19 VaccinesCoronavirusCOVID-19SARS-CoV-2“Vaccine efficacy”

Identifiers

PMID41073977
PMCPMC12512585

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.